Scout | Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

This opportunity is no longer accepting applications.

grant

Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

The National Cancer Institute (NCI) is offering grants to support research involving small molecules that can help understand disease biology or act as treatments. The grant focuses on discovering molecules that are significant to the health outcomes of various NIH Institutes. Research stages covered include: 1) developing assays for biological targets and disease mechanisms to identify small …

Source

Agency: National Institutes of Health

Program: SBIR

Dates

Opportunity Released: August 10, 2023

Submission Deadline: September 7, 2026

Application Window Closes: September 7, 2026

Open for Submission: August 10, 2023

Keywords

assay development

chemical probes

drug discovery

immunomodulators

National Cancer Institute

small molecules

target validation

high-throughput screening

hit-to-lead optimization

medicinal chemistry

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers